Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus and InterMed Discovery Announce Marketing Collaboration

Published: Wednesday, July 20, 2011
Last Updated: Wednesday, July 20, 2011
Bookmark and Share
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.

BioFocus, and InterMed Discovery GmbH (IMD), have announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.

Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus.

BioFocus will then incorporate these as part of its own integrated drug discovery offerings. BioFocus has a track record of service deals with industry for the discovery of active ingredients in pharmaceutical, animal health and agrochemical applications.

“We believe that the combination of our natural product capabilities with the well known discovery capabilities of BioFocus will offer a powerful discovery solution at a time when there is already growing demand from the pharma, veterinary and agro industries to fill depleted pipelines,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.

“We have been impressed with the scale of IMDs natural product discovery capabilities and we believe that when InterMed’s natural product libraries and services are combined with our screening services, our engine for drug discovery will be substantially enhanced and more cost-effective for our clients,” added Dr. Chris Newton, Managing Director BioFocus.

Originally developed within Bayer Healthcare AG, the IMD natural product integrated discovery platform consists of the largest natural compound libraries available to industry and a powerful combination of rich databases of data and research relating to natural compounds.

Together with BioFocus’ screening technologies and integrated discovery capabilities they amount to a strong platform in the discovery of biologically functional natural compounds.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
BioFocus Announces Agreement with ChanTest
BioFocus expands ion channel offering.
Thursday, February 07, 2013
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus Enters Collaboration with Michael J. Fox Foundation
Collaboration agreement for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Thursday, July 14, 2011
BioFocus Extends Collaboration with Usher III Initiative
BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
Wednesday, June 22, 2011
BioFocus Leads Compound Library Market with Innovative Business Model
Libraries are designed to target protein families of particular interest to the subscribers.
Friday, April 15, 2011
BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays
FLT offers a robust, antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.
Monday, April 11, 2011
BioFocus Extends Collaboration with Amgen into 2012
BioFocus has announced that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services.
Friday, December 17, 2010
BioFocus Renews French Research Tax Credit Accreditation
The accreditation allows eligible French companies to benefit from significant tax relief on research carried out by BioFocus on their behalf until 2013.
Wednesday, June 09, 2010
BioFocus to Host Free Webinar on “Unleashing the Power of Computational Chemistry in Hit Finding Campaigns”
Attendees will learn how computational chemistry tools enable cost- and time-efficient HTS campaigns.
Friday, May 07, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-protein Interactions
BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, has announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, May 04, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-Protein Interactions
These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, April 13, 2010
BioFocus boosts Ion Channel Screening Capability
BioFocus has appointed Dr Iain James as Director of Biology and has commissioned an IonWorks Quattro™ high-throughput electrophysiology screening system.
Monday, September 12, 2005
BioFocus collaboration with Mitsubishi

Monday, February 24, 2003
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!